Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the findings of a follow-up study to the Phase III MEDALIST trial (NCT02631070), evaluating the long-term efficacy and safety of luspatercept in erythropoiesis‑stimulating agent (ESA)-intolerant/refractory patients with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts. With long-term follow-up, luspatercept provided a meaningful clinical advantage compared to placebo, with patients experiencing sustained periods of red blood cell transfusion independence (RBC-TI). Over half of patients experienced a cumulative RBC-TI of ≥ 1 year. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.